

**NHS Portsmouth CCG
Fareham and Gosport CCG
South Eastern Hampshire CCG
Portsmouth Hospitals NHS Trust
Solent NHS Trust
Southern Health NHS Foundation Trust**

**PORTSMOUTH AND SOUTH EAST HAMPSHIRE AREA PRESCRIBING
COMMITTEE**

ANNUAL REPORT 2016-17

Introduction

The Area Prescribing Committee (APC) exists to promote evidence-based, safe and cost-effective use of medicines within the local health economy. The APC provides advice and guidance to NHS organisations and health professionals across Portsmouth and South East Hampshire on prescribing and medicines-related issues.

The Area Prescribing Committee (APC) met every two months in 2016-17 in rotation with the Portsmouth Hospitals Trust Formulary and Medicines Group (FMG). This report covers the six meetings held in April 2016 June 2016, August 2016, October 2016, December 2016 and February 2017.

Main functions of the APC

1. Managed introduction of new medicines

The APC considers applications for medicines to be included on the Portsmouth and South East Hampshire Formulary. All medicines require a written proposal to consider addition to the formulary or a change in formulary classification. New medicines that will be prescribed in both primary and secondary care settings require a full submission to assess clinical and cost-effectiveness and estimate the impact across the local health economy in terms of costs, place in treatment pathways, patient safety and any additional service costs. For hospital-only, in-tariff products, product substitutions and licence extensions an abbreviated submission is usually sufficient. Proposals for medicines that will only be used in the hospital setting and have been supported by the PHT Formulary and Medicines Group are ratified by APC prior to listing on the formulary.

2. Implementation of NICE guidance

The APC reviews all published NICE Technology Appraisals (TAs) as a standing agenda item. Implementation advice is prepared for new drug interventions to be commissioned by CCGs that have a positive recommendation in a NICE TA. This consists of a summary of the NICE guidance plus an estimate of the impact on the local health economy and any actions required. NICE TAs for medicines commissioned by NHS England are noted and the medicines will be automatically added to the formulary for use in line with the TA criteria and any associated NHSE policies. The role of the APC is to ensure that new medicines recommended in a NICE TA or NHS England commissioning policy are listed on the Portsmouth and South East Hampshire Prescribing Formulary for prescribing in accordance with any specified criteria. The APC also considers NICE clinical guidelines that include recommendations on pharmacological management and may issue advice on local implementation.

3. Guidance on prescribing responsibility

As part of the consideration of formulary applications the APC will make a recommendation on prescribing responsibility. The classification used on the formulary is as follows:

Status	Description
--------	-------------

GREEN	Primary and Secondary Care (unrestricted) – may be prescribed by GPs, hospital doctors or other qualified prescribers in primary and secondary care
--------------	---

AMBER	For initiation within a specialist service followed by ongoing prescribing in primary care
--------------	--

A SC	For initiation within a specialist service followed by ongoing prescribing in primary care according to published shared care guidance
-------------	--

RED	For initiation and ongoing prescribing in secondary care only. Medicines in this category may be further restricted to use by specific hospital departments only.
------------	---

BLUE	For prescribing in primary care only
-------------	--------------------------------------

Where a medicine will be initiated by a specialist prior to transfer of prescribing responsibility to primary care a written shared care agreement may be required. Shared care guidance is usually requested for medicines that require ongoing monitoring and regular communication between GP and specialist. The Area Prescribing Committee will ensure that shared care guidance meets the needs of primary care prescribers and once approved it will be published on local websites and linked to the online formulary.

4. Approval of guidelines

The APC is responsible for reviewing and giving final approval to drug therapy guidelines that are applicable to primary care and intended for use by healthcare professionals in Portsmouth and South East Hampshire. This includes guidance on drug treatment of mental health conditions developed by Southern Health NHS Foundation Trust or Solent NHS Trust and other medicines-related guidance for use in community services.

5. Medication safety

The APC reviews all new medicine safety information from the MHRA and recommends local action as appropriate. The notes of the Hampshire Medicines Safety Group are included as a standing item on the agenda and any actions identified by this group are considered for local implementation.

6. Horizon scanning

The anticipated financial impact of new NICE recommendations for CCG-commissioned medicines is considered annually as part of the planning process. The formulary pharmacist undertakes regular horizon scanning to identify new products coming to market and facilitate planned submission of formulary applications. The APC may issue interim advice to prescribers as necessary prior to a formulary submission. The aim is to avoid new medicines being adopted into practice in an ad-hoc fashion and to provide early advice on the position of new products for the benefit of local prescribers.

Collaboration with Basingstoke, Southampton and Winchester DPC

The formulary pharmacist attends the Basingstoke, Southampton and Winchester Medicines Evaluation Committee (MEC) and has access to evidence-based evaluations produced for the MEC and DPC. This contributes to collaborative working between the Basingstoke, Southampton and Winchester DPC and the APC and supports consistent decision-making across Hampshire. A common application form for evaluation of new products is available and both the APC and DPC have standing agenda items to note each others recommendations and identify any actions arising from these.

Portsmouth and South East Hampshire Formulary

The Portsmouth and South East Hampshire Prescribing Formulary is well established and acceptance is generally high. In autumn 2016 the three CCGs and PHT agreed to jointly purchase netFormulary software from Nottingham University Hospitals Trust to enable the publication of the

formulary on a dedicated internet site. The formulary was relaunched in January 2017 and is available at www.portsmouthareaformulary.nhs.uk. The online formulary has greatly improved functionality in terms of searching and the ability to include supplementary information with links to local and national guidance. Updating the formulary is a continual process and changes can be made immediately if required for safety reasons.

Wound Management Formulary

The joint Wound Formulary is used by all NHS organisations in Hampshire and a common process for evaluation of new products is in place. The DPC is the lead committee for the approval of changes to the Wound Formulary proposed by the Hampshire Wound Formulary Group and the APC will normally ratify any changes agreed by the DPC without further discussion. A full review of the formulary was carried out in 2016 and the updated formulary document was published in October 2016. A chapter of the online formulary listing the contents of the Hampshire Wound Formulary has also been built.

Regional Medicines Optimisation Committees

In February 2016 the establishment of four Regional Medicines Optimisation Committees to evaluate medicines that are not on the NICE TA work programme was proposed by NHS England. This is intended to replace multiple individual assessments being undertaken by APC and DPCs and local committees will be expected to focus on implementation. The regional committees will be supported by Specialist Pharmacy Services and will also consider a number of other medicines optimisation issues including the timely uptake and use of biosimilar medicines and advising on the decommissioning of low clinical value medicines. The APC has been following the development of these new committees but they are not yet fully operational and the impact on the work of the APC is currently unclear.

Dr Alastair Bateman

GP Prescribing Lead
South Eastern Hampshire Clinical Commissioning Group
Chair

Janet Brember

Formulary Pharmacist
Secretary

APC Membership

CCG GP Prescribing Lead (Chair)

General Practitioner appointed by NHS Portsmouth CCG

General Practitioner appointed by South Eastern Hampshire CCG

General Practitioner appointed by Fareham and Gosport CCG

Medicines Management Lead for South Eastern Hampshire CCG

Medicines Management Lead for Fareham and Gosport CCG

Medicines Management Lead for Portsmouth CCG

Medical Director of Portsmouth Hospitals NHS Trust

PHT Director of Medicines Management and Pharmacy

Up to three clinician representatives from Portsmouth Hospitals NHS Trust nominated by the Medical Director to include the chair of the PHT Formulary and Medicines Group

Clinical Pharmacy Manager nominated by PHT Director of Medicines Management and Pharmacy
Formulary Pharmacist (secretary)

Chief Pharmacist Southern Health NHS Trust (or nominated deputy)

Chief Pharmacist Solent NHS Trust (or nominated deputy)

Local Pharmaceutical Committee Chief Officer (or nominated deputy)

Public Health representative nominated by Portsmouth City Council or Hampshire County Council

Lay member

Nursing representative

Meetings are considered quorate if the following members are present:

1. Two clinicians (one of whom must be a GP)
2. One pharmacist
3. A representative from primary care
4. A representative from secondary care
5. A representative from two CCGs and Portsmouth Hospitals NHS Trust

Appendix 1

Medicines added to the Portsmouth and South East Hampshire Formulary

The following medicines or new uses of medicines were given final approval by the Area Prescribing Committee.

Date	Name	Prescribers	Indication	Formulary	Commissioner*
17.2.17	Odefsey tablets (tenofovir alafenamide/emtricitabine/rilpivirine)	Secondary Care Only	HIV treatment	Added	NHSE
17.2.17	Brivaracetam tablets	Secondary Care Initiated	Refractory epilepsy	Added	
17.2.17	Ibandronic acid 50mg tablets	Secondary Care Initiated	Adjuvant use in post-menopausal breast cancer	Added	
17.2.17	Zoledronic acid for infusion 4mg	Secondary Care Only (off-licence)	Adjuvant use in post-menopausal breast cancer	Amended	
17.2.17	Oxycodone (oral)	Secondary Care Only	Post-op analgesia (orthopaedic day surgery)	Amended	
17.2.17	Lanreotide (Somatuline Autogel)	Secondary Care Only (off- licence)	Reduction of secretions from pancreatic/ enterocutaneous fistulae	Added	
17.2.17	Morphine sulfate 10mg in 10ml Intraside gel	Secondary Care Only (unlicensed)	Acute painful skin reactions due to radiotherapy	Added	
17.2.17	Ketamine 10mg in 10ml prefilled syringe	Secondary Care Only (unlicensed)	Emergency use - DCCQ only	Added	
17.2.17	Nithiodote (sodium nitrite and sodium thisulfate injections)	Secondary Care Only	Antidote for cyanide poisoning.	Added	
17.2.17	Methylthioninium chloride injection (Proveblue)	Secondary Care Only	Methaemoglobinaemia. Septic shock. Ifosfamide-induced encephalopathy	Added	
17.2.17	Bupivacaine 0.1% with fentanyl 2mcg/ml infusion	Secondary Care Only	Epidural/PCEA for renal patients	Added	
17.2.17	Mepolizumab injection	Secondary Care Only	Severe refractory eosinophilic asthma NICE TA 431	Added	NHSE
17.2.17	Sofosbuvir-velpatasvir (Epclusa) tablets	Secondary Care Only	Hepatitis C NICE TA 430	Added	NHSE
17.2.17	Ibrutinib tablets	Secondary Care Only	CLL NICE TA 429	Added	NHSE
17.2.17	Pembrolizumab for infusion	Secondary Care Only	NSCLC NICE TA 428	Amended	NHSE
17.2.17	Pomalidomide tablets	Secondary Care Only	Multiple myeloma NICE TA 427	Added	NHSE
17.2.17	Imatinib tablets	Secondary Care Only	Imatinib resistant CML NICE TA 425	Amended	NHSE
17.2.17	Nilotinib capsules	Secondary Care Only	Imatinib resistant CML NICE TA 425	Amended	NHSE
17.2.17	Dasatinib tablets	Secondary Care Only	Imatinib resistant CML NICE TA 425	Amended	NHSE
17.2.17	Imatinib tablets	Secondary Care Only	Untreated CML NICE TA 426	Amended	NHSE

17.2.17	Nilotinib capsules	Secondary Care Only	Untreated CML NICE TA 426	Amended	NHSE
17.2.17	Dasatinib tablets	Secondary Care Only	Untreated CML NICE TA 426	Amended	NHSE
17.2.17	Pertuzumab for infusion	Secondary Care Only	HER2-positive breast cancer NICE TA 424	Added	NHSE
17.2.17	Eribulin injection	Secondary Care Only	Locally advanced/ metastatic breast cancer NICE TA 423	Added	NHSE
17.2.17	Crizotinib capsules	Secondary Care Only	Previously treated advanced NSCLC NICE TA 422	Amended	NHSE
17.2.17	Everolimus (Afinitor) tablets	Secondary Care Only	Advanced breast cancer NICE TA 421	Added	NHSE
17.2.17	Ticagrelor tablets (60mg)	Secondary Care Initiated	Secondary prevention after MI NICE TA 420	Amended	
16.12.16	Dapagliflozin tablets	Primary and secondary care	Triple therapy in type 2 diabetes NICE TA 418	Amended	
16.12.16	Nivolumab for infusion	Secondary Care Only	Renal cell carcinoma NICE TA 417	Amended	NHSE
16.12.16	Certolizumab pegol injection	Secondary Care Only	Rheumatoid arthritis NICE TA 415	Amended	CCG
16.12.16	Osimertinib tablets	Secondary Care Only	NSCLC NICE TA 416 / CDF	Added	NHSE
16.12.16	Elbasvir/grazoprevir (Zepatier) tablets	Secondary Care Only	Hepatitis C NICE TA 413	Added	NHSE
16.12.16	Leuprorelin (Lutrate) injection	Secondary Care Initiated	Prostate cancer – alternative product	Added	
16.12.16	Flexitol (urea 25%) heel balm	Primary and secondary care	Dry skin conditions affecting feet	Added	
16.12.16	Flexitol (urea 10%) cream	Primary and secondary care	Dry skin conditions	Added	
16.12.16	Descovy tablets (emtricitabine/tenofovir alafenamide)	Secondary Care Only	HIV infection	Added	NHSE
16.12.16	InVita D3 25,000/ml or 50,000/ml liquid (cholecalciferol)	Primary and secondary care	Prescribe by brand name in primary care	Added	
16.12.16	Stexerol D3 25,000 unit tablets (cholecalciferol)	Primary and secondary care	Prescribe by brand name in primary care	Added	
16.12.16	Stexerol D3 1000 unit tablets (cholecalciferol)	Primary and secondary care	Prescribe by brand name in primary care	Added	
16.12.16	Desunin 800 unit tablets (cholecalciferol)	Primary and secondary care	Prescribe by brand name in primary care	Added	
16.12.16	Apremilast tablets	Secondary Care Only	Plaque psoriasis NICE TA 419	Added	CCG
16.12.16	Nepafenac 1mg/ml eye drops	Secondary Care Only	Full course to be supplied by hospital	Added	
16.12.16	Paliperidone (Trevicta) long-acting injection	Secondary Care Only	3-monthly injection	Added	
21.10.16	Testosterone 1% gel (Testim)	Secondary Care Initiated	As part of HRT in women – off-licence	Added	
21.10.16	Utrogestan 100mg capsules	Secondary Care Initiated	HRT – 100mg capsules only	Added	
21.10.16	Qlaira tablets	Secondary Care Initiated	For contraception and relief of symptoms	Added	

			in peri-menopause		
21.10.16	Estradot patches	Primary and secondary care	HRT	Added	
21.10.16	Angeliq tablets	Secondary Care Initiated	HRT – not first line	Added	
21.10.16	Lecicarbon A suppositories	Secondary Care Initiated	Constipation – gastroenterology or urogynaecology only	Added	
21.10.16	Trifluridone-tiparicil tablets	Secondary Care Only	Metastatic colorectal cancer NICE TA 405	Added	NHSE
21.10.16	Enstilar (calcipotriol/ betamethasone) cutaneous foam	Primary and secondary care	Psoriasis (alternative formulation)	Added	
21.10.16	Ivermectin 1% cream	Primary and secondary care	Papulopustular rosacea	Added	
21.10.16	Pemetrexed injection	Secondary Care Only	Non-squamous NSCLC NICE TA 402	Amended	NHSE
21.10.16	Bosutinib tablets	Secondary Care Only	CML NICE TA 401	Added	NHSE
21.10.16	Degarelix injection	Secondary Care Initiated	Advanced prostate cancer NICE TA 404	Added	CCG
21.10.16	Infliximab (biosimilar) for infusion (Remsima)	Secondary Care Only	Prescribe by brand name	Added	CCG
21.10.16	Rasagiline tablets	Secondary Care Initiated	Parkinson's disease	Added	
21.10.16	Secukinumab injection	Secondary Care Only	Ankylosing spondylitis NICE TA 407	Amended	CCG
21.10.16	Aflibercept intravitreal injection	Secondary Care Only	BRVO NICE TA 409	Added	CCG
21.10.16	Talimogene laherparepvec for injection	Secondary Care Only	Unresectable metastatic melanoma NICE TA 410	Added	NHSE
21.10.16	Pegaspargase for injection/infusion	Secondary Care Only	ALL NICE TA 408	Added	NHSE
21.10.16	Crizotinib capsules	Secondary care only	ALK positive NSCLC NICE TA 406	Added	NHSE
19.8.16	Telaprevir tablets	Secondary care only	Discontinued	Deleted	
19.8.16	Nivolumab for infusion	Secondary care only	Advanced melanoma NICE TA 400	Amended	NHSE
19.8.16	Belimumab for infusion	Secondary care only	SLE NICE TA 397	Added	NHSE
19.8.16	Trametinib tablets	Secondary care only	Metastatic melanoma NICE TA 396	Added	NHSE
19.8.16	Dabrafenib tablets	Secondary care only	Metastatic melanoma NICE TA 396	Amended	NHSE
19.8.16	Ceritinib capsules	Secondary care only	NSCLC NICE TA 395	Added	NHSE
19.8.16	Adalimumab injection	Secondary care only	Hidradenitis suppurativa NICE TA 392	Amended	NHSE
19.8.16	Ciclesonide MDI	Secondary Care Initiated	Asthma (over 12s)	Added	
19.8.16	DuoResp Spiromax (budesonide/formoterol DPI)	Primary and secondary care	Asthma and COPD over 18s only	Added	
19.8.16	Ultibro Breezhaler (glycopyrronium/ indacaterol) inhaler	Primary and secondary care	LABA+LAMA for COPD	Added	
19.8.16	Rezolsta tablets (darunavir/cobicistat)	Secondary care only	HIV infection	Added	NHSE
19.8.16	Genvoya tablets (emtricitabine/ elvitegravir/cobicistat/ tenofovir alafenamide fumarate)	Secondary care only	HIV infection	Added	NHSE

19.8.16	Evotaz tablets (atazanavir/cobicistat)	Secondary care only	HIV infection	Added	NHSE
19.8.16	Indocyanine green injection	Secondary care only	Surgical dye (unlicensed)	Added	
19.8.16	Abidec drops	Primary and secondary care	Vitamin supplement	Added	
19.8.16	Evolocumab injection	Secondary care only	Hyperlipidaemia NICE TA 394	Added	CCG
19.8.16	Alirocumab injection	Secondary care only	Hyperlipidaemia NICE TA 393	Added	CCG
19.8.16	Cangrelor injection	Secondary care only	Primary PCI where oral P2Y12 inhibitors cannot be given.	Added	
17.6.16	Pegylated liposomal doxorubicin HCl infusion	Secondary care only	Ovarian cancer NICE TA 389	Amended	NHSE
17.6.16	Paclitaxel for infusion	Secondary care only	Ovarian cancer NICE TA 389	Amended	NHSE
17.6.16	Cabazitaxel for infusion	Secondary care only	Hormone-relapsed metastatic prostate cancer NICE TA 391	Added	NHSE
17.6.16	Abiraterone tablets	Secondary care only	Metastatic hormone-relapsed prostate cancer NICE TA 387	Amended	NHSE
17.6.16	Sacubitril valsartan tablets	Secondary Care Initiated	Symptomatic CHF with reduced ejection fraction NICE TA 388	Added	
17.6.16	Tafluprost/timolol (Taptiqom) unit dose eye drops	Secondary Care Initiated	Preservative free drop for glaucoma	Added	
17.6.16	Canagliflozin tablets	Primary and secondary care	NICE TA 390 (monotherapy)	Amended	
17.6.16	Dapagliflozin tablets	Primary and secondary care	NICE TA 390 (monotherapy)	Amended	
17.6.16	Empagliflozin tablets	Primary and secondary care	NICE TA 390 (monotherapy)	Amended	
15.4.16	Benepali (etanercept biosimilar) injection	Secondary care only	Prescribe by brand name	Added	CCG
15.4.16	Ruxolitinib tablets	Secondary care only	Myelofibrosis NICE TA 386	Added	NHSE
15.4.16	Nivolumab for infusion	Secondary care only	Advanced melanoma NICE TA 384	Added	NHSE
15.4.16	Cilodex (ciprofloxacin /dexamethasone) ear drops	Primary and secondary care	AOM inpatients with grommets, AOE	Added	
15.4.16	Ropinirole tablets	Secondary Care Initiated	Restless legs syndrome-renal palliative care (off-licence), sleep clinic	Amended	
15.4.16	Fosfomycin for infusion	Secondary care only	Consultant microbiologist only	Added	
15.4.16	Ezetimibe tablets	Primary and secondary care	Hypercholesterolaemia NICE TA 385	Amended	
15.4.16	Toujeo prefilled pen (insulin glargine 300units/ml)	Secondary Care Initiated	Concentrated insulin for patients with large insulin requirements to reduce injection volume.	Added	

***Responsible commissioner for high cost drugs excluded from tariff**

Appendix 2

Shared care agreements approved:

Octreotide for acromegaly
Lanreotide for acromegaly
Ciclosporin for severe psoriasis
Rotigotine patches for Parkinson's disease
Riluzole for amyotrophic lateral sclerosis
Melatonin for sleep disorders in children
Licensed ADHD Medications for the Treatment of Childhood ADHD
Nebulised Antibiotics (Gentamicin and Colomycin) for Non-CF Bronchiectasis
Prescribing and Monitoring of Lithium (Solent NHS Trust)
Sacubitril valsartan for the treatment of symptomatic chronic heart failure with reduced ejection fraction
Denosumab (XGEVA®) for the treatment of Bone Metastases in patients with solid tumours other than prostate
Denosumab (Prolia) for Osteoporosis in adults
Bisphosphonates for adjuvant use in breast cancer

Other medicines guidance approved:

Parkinson's disease – drug treatment
Solent Continence Formulary
Community management of Clostridium difficile infection
Constipation guidelines
Dermatology quick reference guides for primary care
Hormone Replacement Therapy
Vitamin D brand options